Proprietary cell line

We have developed a proprietary packaging cell line called Procell92, which enables us to produce our vaccine candidates in line with good manufacturing practice (GMP) and industry-leading productivity.

Procell92 allows the efficient production of adenovirus vectors containing inserts that prevent them from being produced in standard human HEK 293 or fetal PER C6 cells. This is because the inserts encode proteins that interfere with the host cell metabolism, for example proteins with transmembrane domains or proliferative activity. Procell92 has been engineered with a proprietary technology that enables it to produce adenovirus vectors with toxic inserts as efficiently as wild type adenovirus. This technology has been shown to increase productivity even with non-toxic inserts.

Procell92 represents the ultimate cell substrate for the production of any adenovirus-based vaccine vector. The figure below shows the high level of productivity by Procell92 of an adenovirus vector – encoding three toxic hepatitis C proteins – which does not grow in 293 or PER C6 cells.